Enabling next-generation therapeutics through improved endosomal escape

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues, such as muscle, heart, kidney and the brain.
With successful PoCs in rodents and non-human primates, Sapreme is now building a pipeline of therapeutic applications to address high unmet needs in neuromuscular, renal, cardiometabolic diseases and beyond.
Our lead program is designed as a best-in-class therapy for Duchenne muscular dystrophy, an incurable and fatal pediatric monogenic disease. In addition, we are pursuing strategic partnerships to co-develop products with select pharma/biotech companies.

Science

The problem: Less than 1% of next-generation therapeutics cross cellular barriers efficiently

Large molecules do not cross cell- or endosomal membranes efficiently. Therefore, intracellular target engagement is inefficient. This leads to limited new treatment options for patients, despite validated and promising disease targets. There is a high need for improved intracellular delivery of next-generation oligonucleotide therapeutics (siRNAs and ASOs).

 

Our solution: Harnessing the power of endosomal escape enhancers evolved in plant biology

Sapreme has selected a unique class of plant secondary metabolites (glycosylated triterpenoids) that specifically enhance delivery of large molecules to the cellular cytoplasm by mediating endosomal escape. Through advanced chemical modification of these natural compounds, Sapreme has developed a proprietary technology platform (SPT) with optimized medicinal properties. Our SPT platform selectively enhances receptor-targeted delivery to endosomes and enables pH-driven endosomal release of the therapeutic. Endosomal targeting and proprietary linker technology means that SPT remains inactive in circulation and has unprecedented endosomal escape potency and tolerability.

test_coretech3

Team

Executive Management Team

Board of Directors

Jeanne Bolger

Jeanne Bolger

Chair
Marco Timmers

Marco Timmers

CEO
Karl Rothweiler

Karl Rothweiler

Hendrik Zonnenberg

Hendrik Zonnenberg

News & Events

Press Releases

Bilthoven, The Netherlands

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD). Additionally, the company has established its Scientific Advisory Board (SAB), comprised of experts in diseases with high unmet medical need, as well as the rapidly expanding field of RNA delivery. Read the full press release here.

Upcoming Events

No events scheduled ahead

About Sapreme:

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues.

For Media Inquiries, please contact:
Trophic Communications
Desmond James or Valeria Fisher  |  +49 151 67859086 or +49 175 8041816   |  sapreme@trophic.eu

Careers

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76 (Main office Desk)

Address

Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands